Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 221 for:    Recruiting, Not yet recruiting, Available Studies | Acute kidney injury

Strategy for Uptake of Processes for Recognizing and Responding to Acute Kidney Injury (SUPPORT AKI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03564314
Recruitment Status : Recruiting
First Posted : June 20, 2018
Last Update Posted : June 25, 2018
Sponsor:
Collaborators:
Alberta Health Services
University of Alberta
Covenant Health
Information provided by (Responsible Party):
University of Calgary

Brief Summary:
Acute kidney injury (AKI) is common and costly complication of major surgery. AKI can lead to prolonged hospitalization and a higher likelihood of dialysis, chronic kidney disease and death. However, AKI can be reversed when recognized early, by ensuring that patients receive adequate fluids and medications that worsen kidney function or cause toxicity are avoided or appropriately prescribed. Past research suggests that AKI in surgical settings can be missed early in its onset, leading to delayed intervention and progression to more severe stages. The purpose of this project is to implement clinical decision support for early recognition and management of AKI on surgical units in Alberta hospitals, and to determine whether the initiative leads to improvements in the quality of care for AKI, length of hospital stay for patients, and costs to the healthcare system.

Condition or disease Intervention/treatment Phase
Acute Kidney Injury Other: SUPPORT AKI Clinical Decision Support Not Applicable

Detailed Description:

Overview: Cluster-randomized stepped-wedge trial to evaluate the impact of implementing a clinical decision support initiative for early recognition and management of hospital-acquired AKI.

Study Population: Adult patients hospitalized on surgical units in Alberta who develop acute kidney injury will be eligible if not already receiving dialysis.

Intervention: The multidimensional clinical decision support intervention consists of: (1) electronic and non-computerized tools for early recognition of AKI, (2) educational program for clinical staff, (3) decision support resources and guidance for the management of AKI and consultation with specialists.

Study Design: Using a stepped-wedge design, eight general and vascular surgery unit clusters in Calgary (Foothills Medical Centre, Peter Lougheed Centre) and Edmonton (University of Alberta Hospital, Grey Nuns Community Hospital), Alberta will be randomly ordered to be sequentially introduced to the clinical decision support intervention. The pre-implementation period will include all patients admitted to the participating hospital units in the year before the random timing of introduction of the initiative on each participating unit. The post-implementation study cohort will include patients admitted in the year after the random timing of introduction of the initiative on each unit. Analysis of processes of care and outcomes will focus on patients on these units who develop AKI during the pre- and post-implementation time periods (i.e. are eligible to receive care under the AKI decision support initiative). Additionally, health care providers (e.g. physicians, nursing staff, pharmacists) who have direct experience with the clinical decision support tools and processes will be invited to participate in the surveys and interviews pre- and post-implementation.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1206 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Strategy for Uptake of Processes for Recognizing and Responding to Acute Kidney Injury
Actual Study Start Date : March 13, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: SUPPORT AKI Clinical Decision Support
Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
Other: SUPPORT AKI Clinical Decision Support
Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.

No Intervention: Control
Usual care provided to patients with AKI on surgical units.



Primary Outcome Measures :
  1. Progression of AKI [ Time Frame: From date of AKI onset to discharge from hospital, assessed up to 30 days ]
    Incidence of progression of AKI to higher AKI stage (including progression to dialysis or death)


Secondary Outcome Measures :
  1. Length of AKI hospital stay, days [ Time Frame: From date of AKI onset to discharge from hospital, assessed up to 30 days ]
    Mean length of hospital stay from acute kidney injury to discharge

  2. Resource use for AKI [ Time Frame: Duration of index hospital admission, assessed up to 30 days ]
    Mean total health care costs of hospital care during the index admission

  3. Time to initial response to AKI [ Time Frame: From AKI onset up to 48 hours following AKI onset ]
    Time from AKI onset to clinical response with fluid or medication management intervention

  4. Volume intervention (change in fluid or diuretic order) for AKI [ Time Frame: Within 48 hours following AKI onset ]
    New or modified intravenous fluid or diuretic order

  5. Adverse medication exposure [ Time Frame: Within 48 hours following AKI onset ]
    Dose modification or suspension or a medication that may cause AKI or that is cleared by the kidney

  6. Medical consultation for AKI [ Time Frame: Within 7 days of AKI onset ]
    Consultation with nephrology or general internal medicine

  7. Change in estimated Glomerular Filtration Rate (eGFR) [ Time Frame: From most recent baseline eGFR measurement prior to AKI onset to eGFR measurement closest to 3 months after AKI onset ]
    The difference in eGFR from baseline to 3 months after development of AKI

  8. Mortality [ Time Frame: Within 30 days of AKI onset ]
    All cause mortality



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients (18 years of age and older) who develop hospital-acquired acute kidney injury on identified general and vascular surgery units in Alberta

Exclusion Criteria:

  • Hospitalized on non-surgical units
  • Receiving dialysis prior to admission on surgery unit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03564314


Contacts
Layout table for location contacts
Contact: Matthew T James, MD, PhD 4032107317 mjames@ucalgary.ca
Contact: Meha Bhatt, MSc 4032103991 meha.bhatt@ucalgary.ca

Locations
Layout table for location information
Canada, Alberta
Peter Lougheed Centre Active, not recruiting
Calgary, Alberta, Canada, T1Y6J4
Foothills Medical Centre Recruiting
Calgary, Alberta, Canada, T2N2T9
Principal Investigator: Matthew T James, MD, PhD         
University of Alberta Hospital Active, not recruiting
Edmonton, Alberta, Canada, T6G2B7
Grey Nuns Community Hospital Active, not recruiting
Edmonton, Alberta, Canada, T6L5X8
Sponsors and Collaborators
University of Calgary
Alberta Health Services
University of Alberta
Covenant Health
Investigators
Layout table for investigator information
Principal Investigator: Matthew T James, MD, PhD Associate Professor

Layout table for additonal information
Responsible Party: University of Calgary
ClinicalTrials.gov Identifier: NCT03564314     History of Changes
Other Study ID Numbers: REB14-1531
First Posted: June 20, 2018    Key Record Dates
Last Update Posted: June 25, 2018
Last Verified: May 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Calgary:
Acute kidney injury
Major surgery
Clinical decision support

Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases